ArticleBMC cancer2026
Efficacy and safety analysis of TACE combined with lenvatinib and icaritin in unresectable hepatocellular carcinoma with poor performance status.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and icaritin in the treatment of patients with unresectable hepatocellular carcinoma (uHCC) with poor physical condition, aiming to provide a safer and more effective treatment strategy for patients with advanced uHCC and poor physical status. MATERIALS AND
methodsClinical data from 49 patients with uHCC and poor physical condition who received treatment between June 2022 and December 2023 were collected. The patients were divided into two groups based on their treatment method: TACE + LEN+Icaritin group (N = 21) and TACE group (N = 28). The primary endpoints were the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) of the tumor in both groups. The secondary endpoint was the incidence of treatment-related adverse events (AEs) in both groups.
resultsThe ORR and DCR of the TACE + LEN+Icaritin group were significantly higher than those of the TACE group (66.7% vs. 28.6%, P = 0.011; 85.7% vs. 53.6%, P = 0.030). The mPFS of the TACE + LEN+Icaritin group was longer than that of the TACE group (8.6 months vs. 4.1 months, HR = 0.316, 95%CI: 0.166-0.599; P < 0.001). The incidence of hand-foot syndrome (all grades) was higher in the TACE + LEN+Icaritin group compared to the TACE group (P = 0.004), but there was no significant difference in the incidence of grade 3/4 hand-foot syndrome between the two groups (P = 0.429). The incidence of fatigue and anorexia (all grades) was lower in the TACE + LEN+Icaritin group compared to the TACE group (P < 0.05). A total of 66.7% of patients in the TACE + LEN+Icaritin group showed improvement in physical condition after treatment, which was significantly higher than in the TACE group (P = 0.022).
conclusionTACE combined with lenvatinib and icaritin demonstrates good efficacy and safety in the treatment of patients with uHCC and poor physical condition (ECOG = 2). This combination therapy may be a viable option for improving prognosis and quality of life in patients with uHCC and poor physical condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.